提供支持According to Yiou, Dezhan Healthcare has signed a letter of intent for investment with Chang Jiang Mai Medical Technology Industry Group (Chang Jiang Mai) and its largest shareholder Dai Yanzhen. Dezhan Healthcare will acquire a 51.68% stake of Chang Jiang Mai owned by Dai Yanzhen and other affiliated shareholders.
There are two reasons why Dezhan Healthcare wants to acquire Chang Jiang Mai.
On the one hand, the market prospect of Chang Jiang Mai is promising. Chang Jiang Mai is engaged in the disinfection of modern science and technology for more than twenty years, with great achievement in the Chinese modern disinfection technology industry. Chang Jiang Mai is the first disinfection technology enterprise in China to provide services for the disinfection of medical and public health, food hygiene, and other fields of professional disinfection.
Its disinfection products of the "Jian Zhi Su" series have become the leading products in the industry, widely used in public health, medical care, food and beverage drinking water industry, social services, military, railway, civil aviation, schools.
On the other hand, this acquisition can make up for business shortcomings and expand the product pipeline for Dezhan Healthcare. In addition to the development of its own core medical business, Dezhan Healthcare also used acquisitions, capital holding and other ways to expand the business. According to the announcement issued by Dezhan Healthcare on March 9, 2019, it has cooperated with Hanzhong Enterprise Management Group Co., Ltd. and Hanma Investment Group Co., Ltd. in order to develop further in the hemp health industry.
Dezhan Healthcare is committed to the research and development of human life sciences. It focuses on developing cardiovascular and cerebrovascular drugs, cancer drugs, health products, energy drinks, ecological water, and so on. As the leading company in healthcare, the market value of Dezhan Healthcare had exceeded 30 billion yuan by the end of March 2019.
渝公网安备 50011202502165号
